EGFR mutant-specific inhibitor DZD6008
Term · Oncology and biomedicine · MLC-T-ONC-013266
An orally available, blood-brain-barrier (BBB) penetrant, mutant-specific inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, EGFR inhibitor DZD6008 targets, binds to and inhibits certain EGFR mutations. This prevents EGFR-mediated signaling and may result in the inhibition of tumor growth in susceptible tumor cells. EGFR plays a major role in tumor cell proliferation and is often mutated in cancer cells.
| Identifier | MLC-T-ONC-013266 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | EGFR inhibitor DZD6008 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013266",
"term": "EGFR mutant-specific inhibitor DZD6008",
"field": "Oncology and biomedicine",
"definition": "An orally available, blood-brain-barrier (BBB) penetrant, mutant-specific inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, EGFR inhibitor DZD6008 targets, binds to and inhibits certain EGFR mutations. This prevents EGFR-mediated signaling and may result in the inhibition of tumor growth in susceptible tumor cells. EGFR plays a major role in tumor cell proliferation and is often mutated in cancer cells.",
"synonyms": [
"EGFR inhibitor DZD6008"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/egfr-mutant-specific-inhibitor-dzd6008/"
}
Record 6,457 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.